DOACs in elective electrical cardioversion Appendix C. Comparison of outcomes <30 days post-cardioversion in present study to randomized controlled trials focusing on DOAC and elective cardioversion Study OAC group Patients (n) Mean CHA2DS2VASc score CHA2DS2-VASc score ≥2 Stroke/ SEE* ISTH major bleeding* Death* Present study DOAC 488 2.2 ± 1.6 64% 1 (0.20) 1 (0.20) 2 (0.41) X-VeRT (7) Rivaroxaban 978 NA 64% 2 (0.20) 6 (0.61) 5 (0.51) ENSURE-AF (9) Edoxaban 1095 2.6 ± 1.4 77% 3 (0.27) 3 (0.27) 1 (0.09) EMANATE (8) Apixaban 753 2.4 ± 1.7 NA 0 (0) 3 (0.41) 2 (0.27) Present study VKA 943 2.4 ± 1.7 66% 2 (0.21) 1 (0.11) 4 (0.42) X-VeRT (7) VKA 492 NA 63% 3 (0.61) 4 (0.80) 3 (0.61) ENSURE-AF (9) VKA 1104 2.6 ± 1.4 78% 4 (0.36) 5 (0.45) 6 (0.54) EMANATE (8) VKA 747 2.4 ± 1.7 NA 6 (0.80) 6 (0.83) 1 (0.13) Data are presented as number (percentages), unless stated otherwise. *The endpoints given in this table are based on a follow-up of 30 days. Abbreviations: DOAC = direct acting oral anticoagulation; ISTH = International Society of Thrombosis and Haemostasis; NA = not available; OAC = oral anticoagulation; SEE = systemic embolic event; VKA = vitamin K antagonist. 2
RkJQdWJsaXNoZXIy MTk4NDMw